Angelalign TechnologyAGLFF -1.74%73 Return-on-Tangible-Equity is 5.96% as of Dec. 2025, which is 45% below its 10-year median of 10.85. GuruFocus rates AGLFF with a GF Score™ of 73/100 and a GF Value™ of $12.51 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 758 Medical Devices & Instruments companies, Angelalign Technology ranks better than 55.15% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Angelalign Technology's annualized net income for the quarter that ended in Dec. 2025 was $27.6 Mil. Angelalign Technology's average shareholder tangible equity for the quarter that ended in Dec. 2025 was $462.6 Mil. Therefore, Angelalign Technology's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was 5.96%.
The historical rank and industry rank for Angelalign Technology's Return-on-Tangible-Equity or its related term are showing as below:
AGLFF'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 1.56 Med: 10.85 Max: 46.07
Current: 6.22
During the past 8 years, Angelalign Technology's highest Return-on-Tangible-Equity was 46.07%. The lowest was 1.56%. And the median was 10.85%.
AGLFF's Return-on-Tangible-Equity is ranked better than 55.15% of 758
companies
in the Medical Devices & Instruments industry
Industry Median: 4.08
vs AGLFF: 6.22
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Angelalign Technology Return-on-Tangible-Equity Related Terms
Angelalign Technology Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Angelalign Technology's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AGLFF vs ISRG, BDX, MDLN: Return-on-Tangible-Equity Comparison
For the Medical Instruments & Supplies subindustry, Angelalign Technology's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Angelalign Technology Return-on-Tangible-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Angelalign Technology's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Angelalign Technology's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 5.96% mean?
Angelalign Technology (AGLFF) has a Return-on-Tangible-Equity of 5.96% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Angelalign Technology and its competitors. This is 45% below median its historical median of 10.85. Over the past decade, Angelalign Technology's Return-on-Tangible-Equity has ranged from 1.56 to 46.07. According to the industry distribution chart, Angelalign Technology ranks #340 out of 758 companies in the Medical Devices & Instruments industry, placing it in the top 44.9%.
Is Angelalign Technology's Return-on-Tangible-Equity too high?
Angelalign Technology's current Return-on-Tangible-Equity of 5.96% is 45% below median its 10-year median of 10.85. Over the past 10 years, this metric has ranged from a low of 1.56 to a high of 46.07. The Medical Devices & Instruments industry median Return-on-Tangible-Equity is 4.08. Angelalign Technology's value of 5.96% is 46.1% above this industry median. Based on the distribution chart, Angelalign Technology ranks #340 out of 758 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Angelalign Technology has a GF Score™ of 73/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Angelalign Technology's Return-on-Tangible-Equity compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Angelalign Technology ranks #340 out of 758 companies for Return-on-Tangible-Equity. This puts Angelalign Technology in the upper half of its industry. The industry median Return-on-Tangible-Equity is 4.08. Angelalign Technology's value of 5.96% is 46.1% above this benchmark. Historically, Angelalign Technology's own Return-on-Tangible-Equity has ranged from 1.56 to 46.07 over the past decade. While the company's 10-year median is 10.85 vs. the industry median of 4.08, Angelalign Technology has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Devices & Instruments company?
The median Return-on-Tangible-Equity among Medical Devices & Instruments companies is 4.08, based on 758 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Angelalign Technology's current Return-on-Tangible-Equity of 5.96% is 46.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Angelalign Technology and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Equity is 4.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Angelalign Technology's current Return-on-Tangible-Equity is 5.96%, which is 45% below median its own 10-year median of 10.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Angelalign Technology stock overvalued right now?
Based on GuruFocus' analysis, Angelalign Technology (AGLFF) is currently considered Significantly Undervalued. The stock's GF Value™ is $12.51, compared to a current price of $8.77 — trading 29.9% below its estimated fair value. The current Return-on-Tangible-Equity is 5.96%, which is 45% below median its 10-year median of 10.85 and 46.1% above the Medical Devices & Instruments industry median of 4.08. Angelalign Technology's overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Angelalign Technology (AGLFF), the current Return-on-Tangible-Equity is 5.96% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Angelalign Technology (AGLFF) Overvalued in 2026?
Based on GuruFocus' analysis, Angelalign Technology stock appears to be undervalued.
The current stock price of $8.77 is trading 29.9% below its estimated GF Value™ of $12.51.
GuruFocus considers Angelalign Technology to be Significantly Undervalued.
Key valuation signals for AGLFF:
Return-on-Tangible-Equity: 5.96% (45% below median its 10-year median of 10.85)
GF Value™: $12.51 vs. price of $8.77 (29.9% below fair value)
Industry Position: 46.1% above the Medical Devices & Instruments median (#340 of 758)
No single metric tells the full story. See the AGLFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Angelalign Technology Inc is an investment holding company. It is principally engaged in clear aligner treatment solutions, including treatment planning services, manufacturing, and marketing of clear aligners. The company provides dental professionals with self-developed digital orthodontic solutions. The company's Angelalign clear aligner system facilitates dental professionals throughout the entire clear aligner treatment process, including digitally-assisted case assessment support and treatment planning services, provide dental professionals with digitally-assisted case assessment support and treatment planning services, and helps dental professionals design, review, and modify treatment plans.
73GF Score
Get the complete analysis for AGLFF
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AGLFF has been successfully added to your 
